Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Platinum anticancer agent

The interaction of platinum(II) complexes with various amino acids and simple peptides is relevant to understanding the biological fate of platinum anticancer agents such as mplatin, and this area has been reviewed extensively.258-261... [Pg.704]

Figure 2 Structures of the clinically used platinum anticancer agents. Figure 2 Structures of the clinically used platinum anticancer agents.
Farrell, N. Spinelli, S. Dinuclear and Trinuclear Platinum Anticancer Agents In Uses of Inorganic Chemistry in Medicine, Farrell, N., Ed. The Royal Society of Chemistry Cambridge, 1999, pp 124-134. [Pg.836]

Liu, Q. Qu,Y Van Antwerpen, R. Farrell, N. Interaction of Polynuclear Platinum Anticancer Agents. Implications for Gellular Uptake. Biochemistry 2006, 45, 4248-4256. [Pg.675]

GK Poon, P Mistry, S Lewis. Electrospray ionization mass spectrometry of platinum anticancer agents. Biol Mass Spectrom 20 687, 1991. [Pg.190]

Jung, Y. and Lippard, S.J. (2003) Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents. [Pg.431]

Nephrotoxicity is a major side effect of chemotherapy. Evaluating renal toxicity from anticancer drugs uses renal slices and isolated cell suspensions of renal proximal tubules [93]. Cisplatin, cis-diamminedichloroplatinum II (CDDP), is an inorganic platinum anticancer agent that offers broad-spectrum antitumor activity against various types of animal and human tumors [94]. CDDP-induced nephrotoxicity is the most important dose-limiting factor in chemotherapy [87, 95]. Earlier studies have reported that CDDP therapy is related to cardiotoxicity [89]. [Pg.215]

Similar systems contacting ruthenium as active antineoplastic agents has been also proposed. Such complex rappresent and efficient and promising alternative to the platinum anticancer agents. ... [Pg.489]

The clinical utility of platinum anticancer agents is well proved. One leading anticancer agent, cisplatin, is useful in treating some human cancers but is limited by both its side-affects and the ability of some cancer cells to acquire a resistance to the drug [286]. Therefore, it is desirable to develop a new platinum-based anticancer drug with broader spectrum of activity, improved clinical efficacy and reduced toxicity, better than cisplatin. [Pg.31]

See other pages where Platinum anticancer agent is mentioned: [Pg.57]    [Pg.13]    [Pg.268]    [Pg.281]    [Pg.16]    [Pg.494]    [Pg.2173]    [Pg.2176]    [Pg.32]    [Pg.190]    [Pg.520]    [Pg.124]    [Pg.126]    [Pg.128]    [Pg.132]    [Pg.134]    [Pg.184]    [Pg.283]    [Pg.165]    [Pg.169]    [Pg.187]    [Pg.606]    [Pg.283]    [Pg.78]   
See also in sourсe #XX -- [ Pg.397 , Pg.1058 ]



SEARCH



Anticancer agents

Platinum anticancer

Platinum-containing anticancer agents

Trinuclear Platinum Anticancer Agents

© 2024 chempedia.info